Ovarian cancer is the gynecologic malignancy with the highest number of deaths in the United States. Previous studies had found a decreased incidence of female gynecological malignancies after liver transplantation. In order to estimate the incidence of ovarian carcinoma after liver transplantation, we evaluated 1708 consecutive liver transplant recipients from 1984 to 2001. Of them, 770 (43%) were female. Routine follow-ups were performed at 1, 2, 5, and 10 years after transplantation. There were two cases of ovarian carcinoma. Both occurred in recipients with a previous history of breast cancer. Based on these data, we conclude that the incidence of ovarian cancer is 1:385 among all female liver transplant recipients, and 1:6.5 among those with a history of pretransplant breast cancer. We recommend that regular check-ups should be undertaken, especially in the population at highest risk.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1021715305407 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of the trends and associated factors of ovarian cancer in Indonesia: A systematic analysis of the Global Burden of Disease study 1990-2021.
PLoS One
January 2025
Departement of Epidemiology, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia.
Introduction: Ovarian cancer is one of the most lethal gynecological cancers. Despite diagnosis and treatment advances, survival rates have not increased over the past 32 years. This study estimated and reported the global burden of ovarian cancer during the past 32 years to inform preventative and control strategies.
View Article and Find Full Text PDFGranulosa tumors are rare tumors arising from the cells of the sexual cord and stroma of the ovary. They account for 5% of ovarian cancers and 70% of stromal cancers of the sex cords. Retroperitoneal tumors (RPTs) are also rare and develop in the retroperitoneal and subperitoneal space.
View Article and Find Full Text PDFExploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.
J Cancer Res Clin Oncol
January 2025
Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.
Background: Li-Fraumeni syndrome (LFS) is an autosomal dominant tumor predisposition syndrome characterized by a high familial incidence of various malignancies. It results from pathogenic/likely pathogenic heterozygous constitutional variants of the TP53 gene. Due to impaired DNA damage repair, conventional cytotoxic therapies or radiotherapy should be avoided whenever feasible to mitigate the high incidence of treatment-related secondary malignancies in these patients.
View Article and Find Full Text PDFOrganoid development and applications in gynecological cancers: the new stage of tumor treatment.
J Nanobiotechnology
January 2025
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Heping District, Shenyang, 110004, Liaoning, China.
Gynecologic cancers (GCs), including cervical cancer (CC), ovarian cancer (OC), endometrial cancer (EC), as well as vulvar and vaginal cancers, represent major health threats to women, with increasing incidence rates observed globally. Conventional treatments, such as surgery, radiation therapy, and chemotherapy, are often hindered by challenges such as drug resistance and recurrence, contributing to high mortality rates. Organoid technology has emerged as a transformative tool in cancer research, offering in vitro models that closely replicate the tumor cell architecture and heterogeneity of primary cancers.
View Article and Find Full Text PDFAssociation of Polycystic Ovarian Syndrome with Endothelial Health, Cardiovascular Risk, and Cellular Aging.
Fertil Steril
January 2025
Division of Reproductive Endocrinology & Infertility, University of California, San Francisco.
Objective: To study measures of endothelial health, cardiovascular risk, and cellular aging between PCOS patients and a reproductive age normative cohort.
Design: Cross-sectional study.
Subjects: Community-based PCOS patients and a normative ovarian aging cohort as controls, aged 45 or younger at the time of evaluation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!